Cargando…

Bringing pharmacomicrobiomics to the clinic through well‐designed studies

Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Steiner, Heidi E., Patterson, Hayley K., Giles, Jason B., Karnes, Jason H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579385/
https://www.ncbi.nlm.nih.gov/pubmed/35899413
http://dx.doi.org/10.1111/cts.13381
_version_ 1784812169647357952
author Steiner, Heidi E.
Patterson, Hayley K.
Giles, Jason B.
Karnes, Jason H.
author_facet Steiner, Heidi E.
Patterson, Hayley K.
Giles, Jason B.
Karnes, Jason H.
author_sort Steiner, Heidi E.
collection PubMed
description Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes’ influence. Studies aiming to explore drug‐microbiome interactions should be well‐designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well‐designed studies will push the field closer to clinical relevance and implementation.
format Online
Article
Text
id pubmed-9579385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95793852022-10-19 Bringing pharmacomicrobiomics to the clinic through well‐designed studies Steiner, Heidi E. Patterson, Hayley K. Giles, Jason B. Karnes, Jason H. Clin Transl Sci Tutorials Pharmacomicrobiomic studies investigate drug‐microbiome interactions, such as the effect of microbial variation on drug response and disposition. Studying and understanding the interactions between the gut microbiome and drugs is becoming increasingly relevant to clinical practice due to its potential for avoiding adverse drug reactions or predicting variability in drug response. The highly variable nature of the human microbiome presents significant challenges to assessing microbes’ influence. Studies aiming to explore drug‐microbiome interactions should be well‐designed to account for variation in the microbiome over time and collect data on confounders such as diet, disease, concomitant drugs, and other environmental factors. Here, we assemble a set of important considerations and recommendations for the methodological features required for performing a pharmacomicrobiomic study in humans with a focus on the gut microbiome. Consideration of these factors enable discovery, reproducibility, and more accurate characterization of the relationships between a given drug and the microbiome. Furthermore, appropriate interpretation and dissemination of results from well‐designed studies will push the field closer to clinical relevance and implementation. John Wiley and Sons Inc. 2022-08-09 2022-10 /pmc/articles/PMC9579385/ /pubmed/35899413 http://dx.doi.org/10.1111/cts.13381 Text en © 2022 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Tutorials
Steiner, Heidi E.
Patterson, Hayley K.
Giles, Jason B.
Karnes, Jason H.
Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title_full Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title_fullStr Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title_full_unstemmed Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title_short Bringing pharmacomicrobiomics to the clinic through well‐designed studies
title_sort bringing pharmacomicrobiomics to the clinic through well‐designed studies
topic Tutorials
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579385/
https://www.ncbi.nlm.nih.gov/pubmed/35899413
http://dx.doi.org/10.1111/cts.13381
work_keys_str_mv AT steinerheidie bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies
AT pattersonhayleyk bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies
AT gilesjasonb bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies
AT karnesjasonh bringingpharmacomicrobiomicstotheclinicthroughwelldesignedstudies